Sydney-based biopharmaceutical company Pharmaxis (ASX:PXS) has announced the appointment of experienced US-based industry executive Dr Neil Graham to its board of directors.
Dr Graham recently retired as the vice president of Strategic Program Direction at Regeneron where he oversaw the company's pipeline and development of immunology and inflammation products.
Dr Graham previously held senior research positions with Vertex, a company that shares Pharmaxis' focus on cystic fibrosis, as well as Trimeris and XTL Biopharmaceuticals. He has also recently joined Evelo Biosciences as its chief development officer.
According to Pharmaxis chairman Malcolm McComas, “We are delighted to welcome Neil to the Pharmaxis Board. His global career in drug development is directly relevant to our current development assets such as the systemic pan‐LOX inhibitor that will move into phase 2 studies later this year. We look forward to Neil’s involvement in our clinical programs and strategic partnerships.”
The Pharmaxis board also includes former MSD managing director and Medicines Australia chair Will Delaat.
The company recently announced positive results from early-phase studies of its oral anti‐fibrotic pan‐Lysyl Oxidase (LOX) inhibitor PXS‐5505. It said it was progressing to a phase 2 study for the treatment of the rare bone cancer, myelofibrosis.